Current Reports (8-K / 6-K)

Company entered into an underwriting agreement for a public offering of 10,345,000 shares of common stock at $29.00 per share.

Expected net proceeds to the Company are approximately $282 million after underwriting discounts and expenses.

Underwriters have a 30-day option to purchase up to an additional 1,551,750 shares.

Offering is expected to close on or about April 6, 2026, subject to customary closing conditions.

Intended use of proceeds includes funding commercial readiness for barzolvolimab, clinical development, platform growth, and general corporate purposes.

Launched generic methadone hydrochloride 5 mg and 10 mg tablets under Elite Laboratories, Inc. label.

Product indicated for severe pain management and opioid addiction detoxification/maintenance treatment.

2025 annual retail sales for brand and generic methadone tablets were approximately $22 million per IQVIA data.

Press release furnished as Exhibit 99.1, not deemed filed under Section 18 of the Exchange Act.

Priced CNY10 billion aggregate principal amount of CNY-denominated senior unsecured notes in offshore transactions under Regulation S.

Notes consist of CNY7.5 billion 2.05% notes maturing in 2031 and CNY2.5 billion 2.75% notes maturing in 2036.

Proceeds will be used for general corporate purposes, including repayment of certain existing indebtedness and payment of interest.

Notes are not registered under the U.S. Securities Act and may not be offered or sold in the United States or to U.S. persons.

Expected listing on The Stock Exchange of Hong Kong Limited; closing subject to customary conditions.

Priced CNY10 billion aggregate principal amount of CNY-denominated senior unsecured notes in offshore transactions under Regulation S.

Notes consist of CNY7.5 billion 2.05% notes maturing in 2031 and CNY2.5 billion 2.75% notes maturing in 2036.

Proceeds will be used for general corporate purposes, including repayment of certain existing indebtedness and payment of interest.

Notes are not registered under the U.S. Securities Act and may not be offered or sold in the United States or to U.S. persons.

Expected listing on The Stock Exchange of Hong Kong Limited; closing subject to customary conditions.

Attributable gold production of 765,900 ounces for 2025 met the mid-point of guidance, driven by record quarterly output at all operations.

Full-year revenues were $2,852.8 million from sales of 817,800 ounces at an average realized gold price of $3,482 per ounce.

Net earnings attributable to equity holders were $664.4 million for 2025, with adjusted net earnings of $709.2 million.

The company expects 2026 attributable production in the range of 720,000 to 820,000 ounces.

Proven and Probable Mineral Reserves (100% basis) total 9.9 million ounces of gold as of December 31, 2025.

Available liquidity was $868.6 million as of December 31, 2025, with net debt reduced by $514.9 million during the year.

Amended and restated ABL Credit Facility of up to $2,400 million replaces prior $2,600 million facility — reflects reduced committed capacity and refinancing on updated terms.

$130 million First In, Last Out (FILO) tranche retained — preserves incremental senior secured lending layer with distinct priority and pricing.

Interest rates tied to Term SOFR or Base Rate plus spreads ranging from 0.125% to 1.375%, dependent on Daily Average Availability — introduces tiered cost structure linked to liquidity usage.

Maturity set for April 1, 2031, but may accelerate to 91 days before maturity of either the $500 million term loan (if >$100M outstanding) or 6.750% senior notes due 2028 (if >$100M outstanding) — introduces structural maturity linkage to other debt.

Fixed charge coverage ratio covenant of 1.0:1.0 triggered if adjusted aggregate availability falls below greater of $204 million or 10% of Borrowing Base — adds earnings-based compliance requirement not present in prior facility.

Borrowing Base includes 90% of eligible receivables and 90.0–92.5% of net orderly liquidation value of eligible inventory — collateral valuation methodology explicitly disclosed and unchanged from prior practice.

Engaged Geophysical Studies Chile to conduct an IP survey targeting sulphides up to 500 m deep across two grids totaling 37 line km — direct step toward drill target refinement.

Carrizal hosts >12 km of mapped, sampled veining with surface samples including 17.25% Cu and 8.4 g/t Au — confirms high-grade potential but management cautions on selectivity of rock samples.

Drilling has tested only 1.5 km of the >12 km veining to ~200 m depth — IP survey aims to extend understanding of mineralization continuity and depth extent.

Next steps include structural interpretation, 3D IP inversion, LiDAR-assisted modeling, and integration with surface sampling to enhance drill targeting confidence.

Executive Vice President Robert F. Buesinger will transition to Special Advisor to the President effective April 2, 2026.

Brian Powers was appointed as Senior Vice President, Performance & Essential Materials Segment Head effective April 2, 2026.

The changes are connected to Mr. Buesinger's upcoming retirement.

The Board of Directors approved both the transition and appointment on March 30, 2026.

The leadership change affects the Performance & Essential Materials segment management.

Sold ~$5M worth of common stock (par value $0.001/share) on April 1, 2026.

Sale price based on NAV per share as of March 31, 2026; NAV and share count to be disclosed within 20 business days.

Shares to be credited to investor accounts as of April 1, 2026; Form 8-K amendment to follow.

No underwriting discounts or commissions paid.

Exempt from Securities Act registration under Section 4(a)(2) and Rule 506(b) of Regulation D.

No general solicitation or public offering conducted.

The First Amendment to the Merger Agreement revises the definition of 'Fully-Diluted Company Shares' and introduces new terms for 'In-the-Money Vested Company Options' and 'In-the-Money Unvested Company Options'.

Certain holders of Teamshares preferred stock may elect to receive a liquidation preference at closing, forfeiting their right to future earnout shares.

The amendment increases the shares reserved for the post-closing Incentive Plan from 5% to 7% of outstanding common stock and adds an annual evergreen increase.

A new employee stock purchase plan (ESPP) will be submitted for shareholder approval, reserving shares equal to 2% of post-closing outstanding common stock.

Execution of employment agreements by each member of the Management Team is now a condition to closing for Live Oak.

A separate Second Letter Agreement Amendment releases up to 1,150,000 Incentive Founder Shares from transfer restrictions at closing if used to secure financing or non-redemption commitments.

The First Amendment to the Merger Agreement revises the definition of 'Fully-Diluted Company Shares' and introduces new terms for 'In-the-Money Vested Company Options' and 'In-the-Money Unvested Company Options'.

Certain holders of Teamshares preferred stock may elect to receive a liquidation preference at closing, forfeiting their right to future earnout shares.

The amendment increases the shares reserved for the post-closing Incentive Plan from 5% to 7% of outstanding common stock and adds an annual evergreen increase.

A new employee stock purchase plan (ESPP) will be submitted for shareholder approval, reserving shares equal to 2% of post-closing outstanding common stock.

Execution of employment agreements by each member of the Management Team is now a condition to closing for Live Oak.

A separate Second Letter Agreement Amendment releases up to 1,150,000 Incentive Founder Shares from transfer restrictions at closing if used to secure financing or non-redemption commitments.

The First Amendment to the Merger Agreement revises the definition of 'Fully-Diluted Company Shares' and introduces new terms for 'In-the-Money Vested Company Options' and 'In-the-Money Unvested Company Options'.

Certain holders of Teamshares preferred stock may elect to receive a liquidation preference at closing, forfeiting their right to future earnout shares.

The amendment increases the shares reserved for the post-closing Incentive Plan from 5% to 7% of outstanding common stock and adds an annual evergreen increase.

A new employee stock purchase plan (ESPP) will be submitted for shareholder approval, reserving shares equal to 2% of post-closing outstanding common stock.

Execution of employment agreements by each member of the Management Team is now a condition to closing for Live Oak.

A separate Second Letter Agreement Amendment releases up to 1,150,000 Incentive Founder Shares from transfer restrictions at closing if used to secure financing or non-redemption commitments.

Units (PAACU) can be separated into ordinary shares (PAAC) and warrants (PAACW) starting April 6, 2026.

Each unit consists of one ordinary share and one-half of one redeemable warrant.

Whole warrants entitle holders to purchase one ordinary share for $11.50 per share.

Holders must contact Continental Stock Transfer & Trust Company through their brokers to separate units.

The company is a blank check company that has not selected a business combination target.

The company will consolidate its Class A ordinary shares at a 1-for-3 ratio, reducing issued shares from 4,686,248 to approximately 1,562,083.

The consolidation is intended to increase the per share trading price to meet Nasdaq's minimum bid price requirement for continued listing.

Post-consolidation trading under the symbol 'CHR' will begin on April 7, 2026, with a new CUSIP number G39973139.

No fractional shares will be issued; any fractional shares resulting from the consolidation will be rounded up to the next whole number.

Outstanding warrants and other equity rights will be proportionately adjusted to reflect the share consolidation.

The Annual General Meeting is scheduled for May 5, 2026, at 2:30 p.m. ET in a virtual-only format.

2025 attributable gold production reached approximately 765,900 ounces, a 15% year-over-year improvement.

Two directors, Dr. Ann Masse and Ms. Audra Walsh, are not standing for re-election at the upcoming AGM.

Daniel Racine is standing for election to the Board, bringing over 35 years of global mining leadership experience.

Shareholders will vote on amendments to the Share Incentive Plan and an advisory resolution on executive compensation.

H25D-6083 intersected 53.4m at 304.14 g/t Ag and 1.33 g/t Au (4.86 g/t AuEq), including 0.9m at 2,890 g/t Ag and 33.70 g/t Au (67.26 g/t AuEq).

New structural intersection identified at Vortex, expanding targets at depth and along strike.

Q1 2026 ended with $189M unrestricted cash, debt free.

Q1 pre-tax expenses of $33.8M from compensation actions, using $19.4M cash.

Expanding exploration with two additional core rigs at Vortex and Brimstone.

Updated corporate presentation posted on website April 2, 2026.

Veea converted $16.9 million in promissory notes held by affiliate NLabs Inc. into 168,764 shares of Series A Preferred Stock.

The company also converted $4.3 million in unpaid rent obligations to NLabs and 83 rd Street LLC into 43,236 shares of the same Preferred Stock.

In connection with the note conversion, Veea issued a warrant to NLabs to purchase 33,551,486 shares of common stock at $0.503 per share.

The company is transferring its listing from the Nasdaq Global Market to the Nasdaq Capital Market to gain additional time to meet minimum bid price and market value requirements.

The conversions were intended to ensure the company's stockholders' equity would be at least $5 million, aiding compliance with Nasdaq Capital Market listing rules.

Veea converted $16.9 million in promissory notes held by affiliate NLabs Inc. into 168,764 shares of Series A Preferred Stock.

The company also converted $4.3 million in unpaid rent obligations to NLabs and 83 rd Street LLC into 43,236 shares of the same Preferred Stock.

In connection with the note conversion, Veea issued a warrant to NLabs to purchase 33,551,486 shares of common stock at $0.503 per share.

The company is transferring its listing from the Nasdaq Global Market to the Nasdaq Capital Market to gain additional time to meet minimum bid price and market value requirements.

The conversions were intended to ensure the company's stockholders' equity would be at least $5 million, aiding compliance with Nasdaq Capital Market listing rules.

QIND's fiscal year 2025 revenue grew 45.9% to $16.3 million, with non-GAAP adjusted net income of $564,465 versus a prior year loss.

QIND wrote off approximately $3.5 million in non-recoverable assets and reduced accounts payable by 45% during fiscal year 2025.

For fiscal year 2026, QIND targets approximately $20 million in revenue, driven by expansion of its Al Shola Gas subsidiary.

QIND's gross margin declined to 29.4% in fiscal year 2025 from 35.5% in the prior year.

The company cited risks including potential disruptions from ongoing conflicts in the Persian Gulf region affecting operations.

Purchased 351,297 ordinary shares from JP Morgan Securities plc on 1 April 2026.

Price range: £10.7000 lowest to £10.8900 highest, average £10.7939 per share.

Shares to be cancelled, reducing issued shares to 2,526,599,459.

Total voting rights now 2,526,599,459 for FCA disclosure calculations.

Repurchase under 2025 AGM authority via arrangement announced 6 January 2026.

On-exchange transaction on London Stock Exchange per Listing Rules.

Purchased 351,297 ordinary shares from JP Morgan Securities plc on 1 April 2026.

Price range: £10.7000 lowest to £10.8900 highest, average £10.7939 per share.

Shares to be cancelled, reducing issued shares to 2,526,599,459.

Total voting rights now 2,526,599,459 for FCA disclosure calculations.

Repurchase under 2025 AGM authority via arrangement announced 6 January 2026.

On-exchange transaction on London Stock Exchange per Listing Rules.

Petrobras’ participation in the Tupi Shared Reservoir increased from 67.216% to 67.457% effective December 1, 2025, strengthening its operator control and revenue entitlement.

Petrobras received ~R$3 billion from consortium partners Shell and Petrogal on March 31, 2026, reflecting retroactive settlement of pre-redetermination volumes and expenses.

Petrobras paid ~R$600 million to the Federal Government (via PPSA) on March 31, 2026, as part of the same redetermination settlement, recognizing the government’s increased share to 0.833%.

The Tupi Shared Reservoir comprises three components: BM-S-11 Concession (Petrobras 65%, Shell 25%, Petrogal 10%), Tupi South Block (Petrobras 100%), and Non-Contracted Area (PPSA-owned), all governed under the AIP framework.

The Iracema reservoir is explicitly excluded from the Tupi AIP and retains prior consortium participation shares.

Petrobras’ participation in the Tupi Shared Reservoir increased from 67.216% to 67.457% effective December 1, 2025, strengthening its operator control and revenue entitlement.

Petrobras received ~R$3 billion from consortium partners Shell and Petrogal on March 31, 2026, reflecting retroactive settlement of pre-redetermination volumes and expenses.

Petrobras paid ~R$600 million to the Federal Government (via PPSA) on March 31, 2026, as part of the same redetermination settlement, recognizing the government’s increased share to 0.833%.

The Tupi Shared Reservoir comprises three components: BM-S-11 Concession (Petrobras 65%, Shell 25%, Petrogal 10%), Tupi South Block (Petrobras 100%), and Non-Contracted Area (PPSA-owned), all governed under the AIP framework.

The Iracema reservoir is explicitly excluded from the Tupi AIP and retains prior consortium participation shares.

Submitted Notice of Intent (NOI) for underground drilling at SM-18 to verify and potentially expand mineral resources.

Drilling supports preparation of comprehensive Plan of Operations targeted for later 2026, advancing SM-18 toward production as fourth mine.

SM-18 joins Velvet-Wood, Slick Rock, and JD-8 as flagship mines feeding into 100%-owned Shootaring Canyon Mill.

Shootaring Canyon Mill expansion to 1,000 tpd and 3M lbs U3O8 annual capacity under UDEQ review.

Historical DOE resource estimate at SM-18: 1,200,000 lbs U3O8; past production: 133,637 lbs U3O8, 575,224 lbs V2O5.

Underground workings at SM-18 in good condition with preserved infrastructure facilitating efficient access.

The filing is a procedural 6-K submission with no disclosed financial results, earnings, or operating metrics.

No executive changes, acquisitions, debt issuances, or material agreements are described in the document.

Exhibit 99.1 is identified as a 'Market release' but its content is not provided and cannot be analyzed.

The filing is a procedural 6-K submission with no disclosed financial results, earnings, or operating metrics.

No executive changes, acquisitions, debt issuances, or material agreements are described in the document.

Exhibit 99.1 is identified as a 'Market release' but its content is not provided and cannot be analyzed.

Converted 146 new homes from inventory to revenue-generating rental homes, increasing total rental homes to ~11,200 — supports near-term revenue growth and occupancy leverage.

Rental home occupancy rose to 94.6%, up 80 bps from 93.8% in Q4 2025 — reflects continued demand strength and operational execution.

Gross home sales revenue was $7.2 million, up 8% from $6.7 million in Q1 2025 — indicates sustained pricing power and community-level demand.

Total occupancy increased by 184 units to 87.7%; same-property occupancy rose by 171 units QoQ and 412 units YoY to 89% — signals broad-based portfolio improvement.

April 2026 rental and related charges increased ~10% year-over-year, with same-property charges up 9.3% — demonstrates successful rent growth implementation across the portfolio.

88 homes are on-site and ready for occupancy, with 405 more being set up — provides visibility into continued occupancy and revenue growth through Q2 2026.

Converted 146 new homes from inventory to revenue-generating rental homes, increasing total rental homes to ~11,200 — supports near-term revenue growth and occupancy leverage.

Rental home occupancy rose to 94.6%, up 80 bps from 93.8% in Q4 2025 — reflects continued demand strength and operational execution.

Gross home sales revenue was $7.2 million, up 8% from $6.7 million in Q1 2025 — indicates sustained pricing power and community-level demand.

Total occupancy increased by 184 units to 87.7%; same-property occupancy rose by 171 units QoQ and 412 units YoY to 89% — signals broad-based portfolio improvement.

April 2026 rental and related charges increased ~10% year-over-year, with same-property charges up 9.3% — demonstrates successful rent growth implementation across the portfolio.

88 homes are on-site and ready for occupancy, with 405 more being set up — provides visibility into continued occupancy and revenue growth through Q2 2026.

The company filed its audited Financial Statements, Management Discussion and Analysis, Annual Information Form, and Annual Report on Form 40F for the year ending December 31, 2025.

The audited consolidated financial statements contained an audit report with a going concern emphasis of matter from the independent registered public accounting firm.

The going concern emphasis is consistent with previous years and does not represent a change or amendment to the company's filings.

The release of this information is required by Section 610(b) of the NYSE American Company Guide.

Common Stock quarterly dividend set at $0.225 per share, implying a $0.90 annual rate.

Series D Preferred Stock quarterly dividend declared at $0.3984375 per share.

Both dividends are payable on June 15, 2026, to shareholders of record on May 15, 2026.

The Series D Preferred Stock dividend covers the period from March 1, 2026, through May 31, 2026.

Common Stock quarterly dividend set at $0.225 per share, implying a $0.90 annual rate.

Series D Preferred Stock quarterly dividend declared at $0.3984375 per share.

Both dividends are payable on June 15, 2026, to shareholders of record on May 15, 2026.

The Series D Preferred Stock dividend covers the period from March 1, 2026, through May 31, 2026.

FDA granted Fast Track designation to CTIM-76 for platinum-resistant ovarian cancer in patients who have received all standard of care therapies.

CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody currently in a Phase 1 clinical trial for CLDN6-positive advanced or metastatic cancers.

Interim data from the CTIM-76 Phase 1a trial is expected in June 2026, which will evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity.

The Fast Track designation is designed to expedite development and review timelines for drugs treating serious conditions with unmet medical needs.

CTIM-76 targets CLDN6, which is enriched in various solid tumors including ovarian, endometrial, lung, gastric, and testicular cancers.

Closed acquisition of Gage Project (5,916 hectares, 181 mining claims) from Liberty Gold USA for 420,935 common shares.

Assumed 4.0% royalty on SITLA leases (8.0% for fissionable materials) and granted 2.0% NSR royalty to seller with 1.0% repurchase option for US$2M.

Appointed Reza Ehsani, with 29+ years experience, as SVP Projects after key contributions to project portfolio.

Transaction at arms' length with no finders' fees.

Gage Project expands Blue Moon's portfolio of 5 brownfield polymetallic projects in critical metals.

GSK purchased 345,000 ordinary shares on April 1, 2026, at a volume-weighted average price of 2,106.14p per share.

The purchase was executed by BNP Paribas SA under a non-discretionary agreement announced on February 17, 2026.

Following the purchase, GSK holds 256,457,615 ordinary shares in treasury, representing 6.32% of total voting rights.

The company has purchased 16,566,521 ordinary shares since February 17, 2026, under its buyback programme.

Total ordinary shares in issue, excluding treasury shares, are 4,059,722,166, which is also the total number of voting rights.

GSK purchased 345,000 ordinary shares on April 1, 2026, at a volume-weighted average price of 2,106.14p per share.

The purchase was executed by BNP Paribas SA under a non-discretionary agreement announced on February 17, 2026.

Following the purchase, GSK holds 256,457,615 ordinary shares in treasury, representing 6.32% of total voting rights.

The company has purchased 16,566,521 ordinary shares since February 17, 2026, under its buyback programme.

Total ordinary shares in issue, excluding treasury shares, are 4,059,722,166, which is also the total number of voting rights.

Med Tech segment sales grew 19.0% YoY to $37.3 million, driven by double-digit growth in Auryon, Mechanical Thrombectomy, and NanoKnife platforms.

GAAP net loss was $8.1 million ($0.19/share); Adjusted EBITDA was $1.8 million, up from $1.3 million in the prior-year quarter.

Company raised FY2026 net sales guidance to $313.5-$315.5M and Adjusted EBITDA guidance to $10.0-$12.0M.

Gross margin declined 110 bps YoY to 52.9%, primarily due to tariff impacts and manufacturing transition costs.

Company ended the quarter with $37.8 million in cash and a debt-free balance sheet.

Entered Sales Agreement with Craft Capital Management LLC on March 18, 2026 for ATM offerings up to US$20 million.

Issued 1,247,456 Class A Ordinary Shares by March 31, 2026, generating gross proceeds of US$0.72 million.

Net proceeds of US$0.69 million after 4% sales agent commission and offering expenses.

4,748,740 Class A Ordinary Shares issued and outstanding as of filing date.

Plans to use proceeds for North American expansion including product portfolio, manufacturing localization, compliance, go-to-market infrastructure, and working capital.

Acquired 150 MW Briscoe Wind Farm in West Texas for a total purchase price of $53.0 million, financed through cash on the balance sheet and debt.

Projected Year-One Adjusted EBITDA of $6 million to $11 million and annualized revenue of $20.0 million to $24.4 million from the acquisition.

Achieves full vertical integration for Project Dorothy, owning both the renewable energy source and the data center infrastructure it powers.

Positions the company to unlock development of Project Dorothy 3, a planned 300 MW+ renewable-powered AI campus expansion on 300 new adjacent acres.

The acquisition is expected to be immediately accretive and provide immediate and significant cash flow.

Acquired 150 MW Briscoe Wind Farm in West Texas for a total purchase price of $53.0 million, financed through cash on the balance sheet and debt.

Projected Year-One Adjusted EBITDA of $6 million to $11 million and annualized revenue of $20.0 million to $24.4 million from the acquisition.

Achieves full vertical integration for Project Dorothy, owning both the renewable energy source and the data center infrastructure it powers.

Positions the company to unlock development of Project Dorothy 3, a planned 300 MW+ renewable-powered AI campus expansion on 300 new adjacent acres.

The acquisition is expected to be immediately accretive and provide immediate and significant cash flow.

Raul Vazquez stepped down as CEO and board member effective April 3, 2026, and will serve as a non-employee advisor until July 3, 2026 — signaling an orderly but definitive leadership change.

Kathleen Layton (Chief Legal Officer) and Gaurav Rana (SVP, General Manager, Lending) were appointed co-principal executive officers effective April 4, 2026, to jointly lead the company on an interim basis.

Each interim leader received a $35,000 monthly base salary increase — raising Layton’s monthly rate from $37,500 to $72,500 and Rana’s from $36,313 to $71,313 — for the duration of their interim roles.

The Board confirmed no family relationships or material interests exist between Layton or Rana and other directors or executives, and no third-party arrangements governed their appointments.

Leiden Dworak resigned as Vice President of Finance and principal accounting officer, effective April 10, 2026.

The resignation was not due to any disagreements with the company regarding operations, policies, or practices.

CFO Jason A. Amello was appointed as the new principal accounting officer, effective April 10, 2026.

Mr. Amello will not receive additional compensation for assuming the principal accounting officer role.

Revenue decreased to $82.6 million in 2025 from $85.9 million in 2024 due to lower gold production.

Profit increased significantly to $101.2 million in 2025 from $3.6 million in 2024, largely due to non-cash items including a $158.8 million gain from earnout liability revaluation.

Gold production was approximately 25,000 ounces in 2025, with cash costs increasing to $1,653 per ounce from $1,150 per ounce in 2024.

Tulani Sikwila was appointed Chief Executive Officer in March 2026, strengthening the leadership team.

The Company provided 2026 guidance for production of 28,000 to 31,500 ounces and adjusted EBITDA of $50 million to $62 million.

Dewatering activities at the Redwing Mine commenced on January 29, 2026, with completion expected by late 2026.

Revenue decreased to $82.6 million in 2025 from $85.9 million in 2024 due to lower gold production.

Profit increased significantly to $101.2 million in 2025 from $3.6 million in 2024, largely due to non-cash items including a $158.8 million gain from earnout liability revaluation.

Gold production was approximately 25,000 ounces in 2025, with cash costs increasing to $1,653 per ounce from $1,150 per ounce in 2024.

Tulani Sikwila was appointed Chief Executive Officer in March 2026, strengthening the leadership team.

The Company provided 2026 guidance for production of 28,000 to 31,500 ounces and adjusted EBITDA of $50 million to $62 million.

Dewatering activities at the Redwing Mine commenced on January 29, 2026, with completion expected by late 2026.

Net sales were $1.1 billion for Q2 FY2026, up 5% year-over-year — reflects broad-based growth despite ABL segment decline.

Operating profit was $133 million, up 21% YoY; operating margin expanded 160 bps to 12.6%, indicating improved cost discipline and mix.

Diluted EPS was $3.09, up 26% YoY; adjusted diluted EPS was $4.14, up 11% YoY — highlights impact of special charges on GAAP results.

ABL segment net sales declined 2.8% YoY to $817.4 million, while AIS segment surged 41% YoY to $248.1 million, aided by an extra month of QSC performance.

Company increased quarterly dividend by 18% to $0.20 per share and repurchased $106 million of common stock year-to-date through February 28, 2026.

Ryanair Mar 2026 guests: 15.8m vs 15.0m in Mar 2025 (+5%)

Mar 2026 load factor: 93% (flat vs Mar 2025)

Over 88,000 flights operated in Mar 2026

Rolling 12-month guests: 208.4m vs 200.2m (+4%)

Rolling 12-month load factor: 94% (flat)

Ryanair Mar 2026 guests: 15.8m vs 15.0m in Mar 2025 (+5%)

Mar 2026 load factor: 93% (flat vs Mar 2025)

Over 88,000 flights operated in Mar 2026

Rolling 12-month guests: 208.4m vs 200.2m (+4%)

Rolling 12-month load factor: 94% (flat)

Record date for Ordinary Shares is close of business on Friday, April 24, 2026, Hong Kong time.

Hong Kong branch transfers must be lodged by 4:30 p.m. on April 24, 2026, Hong Kong time with Computershare Hong Kong.

Cayman Islands principal register transfers due by 6:00 p.m. on April 23, 2026, Cayman time with Maples Fund Services.

ADS holders as of April 24, 2026, New York time, can instruct Deutsche Bank Trust Company Americas on voting Class A shares.

ADS holders canceling ADSs on April 24, 2026, New York time, lose voting eligibility for both ADS instructions and direct attendance.

Common shares begin trading on the TSX under symbol 'ELE' at market open on April 7, 2026.

The Company's shares will be voluntarily delisted from the TSX Venture Exchange concurrently with the TSX listing.

The listing does not involve any concurrent financing, and no new shares were issued.

CEO David M. Cole stated the TSX listing will enhance visibility and broaden the shareholder base.

Adagene is conducting a $70.0 million public offering of 18,666,000 ADSs at $3.75 each — direct equity capital raise to fund operations and development.

Each ADS represents 1.25 ordinary shares, implying issuance of 23,332,500 newly issued ordinary shares — dilutive to existing shareholders.

Leerink Partners and LifeSci Capital serve as joint book-running managers, with Lucid Capital Markets as co-manager — reflects established underwriter relationships in biotech.

Offering is made under an effective Form F-3 shelf registration (File No. 333-287161), declared effective May 30, 2026 — enables efficient, timely capital access.

3,750 new Class A Ordinary Shares were issued on April 1, 2026, from the exercise of share options at USD 0.5 per share.

The company repurchased 590,280 shares on April 1, 2026, on the Nasdaq Global Select Market for an aggregate price of approximately USD 3.99 million.

The repurchase price ranged from USD 6.725 to USD 6.825 per share, with all repurchased shares designated for cancellation.

As of April 1, 2026, 6,323,810 shares have been repurchased under the current mandate, representing 0.6903% of issued shares.

A moratorium on new share issuances is in effect until May 1, 2026, following the repurchase activity.